Purpose and Summary
H.R. 4273 reauthorizes the Over-the-Counter Monograph Drug User Fee Program (OMUFA) for fiscal years 2026 to 2030.
house · Committee report
OVER-THE-COUNTER MONOGRAPH DRUG USER FEE AMENDMENTS
2025-09-17
H.R. 4273 reauthorizes the Over-the-Counter Monograph Drug User Fee Program (OMUFA) for fiscal years 2026 to 2030.
The Coronavirus Aid, Relief, and Economic Security Act (CARES Act), signed into law in March 2020, authorized the Food and Drug Administration (FDA) to assess and collect user fees dedicated to over-the-counter (OTC) monograph drug activities through the OTC Monograph Drug User Fee Program (OMUFA I). Under OMUFA, fees paid by the regulated industry support FDA's regulatory activities related to OTC monograph drugs, while the FDA commits to adhere to certain negotiated performance goals and procedures related to various OTC monograph activities.\1\ --------------------------------------------------------------------------- \1\U.S. Food and Drug Admin., Over-The-Counter Monograph Drug User Fee Program (OMUFA) (2025), https://www.fda.gov/industry/fda-user-fee- programs/over-counter-monograph-drug-user-fee-program-omufa. --------------------------------------------------------------------------- Reauthorization of this program would include the negotiated agreement on performance goals and procedures between FDA and industry for the upcoming five-year period. This would be the first reauthorization of OMUFA (OMUFA II).
On July 16, 2025, the Subcommittee on Health held a hearing on H.R. 4273. The title of the hearing was ``Legislative Proposals to Maintain and Improve the Public Health Workforce, Rural Health, and Over-the-Counter Medicines.'' The Subcommittee received testimony from: Dr. Jacqueline Corrigan-Curay, JD, MD, Acting Director for Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration; Dr. Candice Chen, MD, MPH, Acting Associate Administrator for Health Workforce, U.S. Health Resources and Services Administration; and Tom Morris, MPA, Associate Administrator for Rural Health Policy, U.S. Health Resources and Services Administration. On July 23, 2025, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 4273, as amended, favorably reported to the House by a record vote of 51 yeas and 0 nays.
Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held hearings and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 4273 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.
Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to reauthorize the Over-the-Counter Monograph Drug User Fee Program (OMUFA) for fiscal years 2026 to 2030. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 4273 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearings were used to develop or consider H.R. 4273: On April 1, 2025, the Subcommittee on Health held a hearing on H.R. 4273. The title of the hearing was ``Examining the FDA's Regulation of Over-the- Counter Monograph Drugs.'' The Subcommittee received testimony from: Kevin Menzel, Member, Board of Directors, Consumer Healthcare Products Association; President, Focus Consumer Healthcare; Douglas M. Troutman, Interim Co- Chief Executive Officer, American Cleaning Institute; Kim Wezik, MPH, Director of Advocacy, Melanoma Research Foundation; Scott Faber, Senior Vice President, Government Affairs, Environmental Working Group; and Carl D'Ruiz, MPH, Senior Science, Advocacy, and Business Development Manager for Beauty and Care, North America, dsm-firmenich. On July 16, 2025, the Subcommittee on Health held a hearing on H.R. 4273. The title of the hearing was ``Legislative Proposals to Maintain and Improve the Public Health Workforce, Rural Health, and Over-the- Counter Medicines.'' The Subcommittee received testimony from: Dr. Jacqueline Corrigan-Curay, JD, MD, Acting Director for Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration; Dr. Candice Chen, MD, MPH, Acting Associate Administrator for Health Workforce, U.S. Health Resources and Services Administration; and Tom Morris, MPA, Associate Administrator for Rural Health Policy, U.S. Health Resources and Services Administration. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 4273 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides a short title of ``Over-the-Counter Monograph Drug User Fee Amendments.'' Section 2. Finding Section 2 reports that Congress finds the fees authorized in this legislation will be dedicated to OTC monograph drug activities. Section 3. Definitions Section 3 amends the definition of a Tier 2 OTC monograph order request to add a new category of such requests, specifically for the addition or modification of certain testing procedures in the applicable monograph(s). Section 4. Authority to assess and use OTC monograph fees Section 4 authorizes the Secretary to continue to assess and collect fees as determined by an annual base revenue amount with certain permitted adjustments, as well as to continue the 10-week operating reserve. This Section also makes certain changes to the process of setting annual facility fees, including changes to the required timelines. Section 5. Reauthorization; reporting requirements Section 5 reauthorizes the requirements included in OMUFA I for the Secretary to prepare and issue certain reports to Congress related to OTC monograph drug activities, including progress made towards the negotiated performance goals. Section 6. Regulation of certain nonprescription drugs that are marketed without an approved drug application Section 6 clarifies that organizations nominated by sponsors or requestors to represent their interests are permitted to meet with FDA officials related to obtaining advice on certain information to support submissions relevant to nonprescription drugs. This section also makes a technical correction to clarify that both sponsors and requestors are permitted to pursue formal dispute resolutions related to certain administrative orders. Section 7. Sunset dates Section 7 establishes sunsets for certain authorities outlined within this legislation. Section 8. Effective date Section 8 specifies the effective date for the amendments in this legislation and ensures that certain fees can be assessed and collected beginning October 1, 2025. Section 9. Savings clause Section 9 preserves the applicability of the previous OMUFA I fee authority with respect to fees due and payable prior to enactment of the amendments made by this legislation. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): FEDERAL FOOD, DRUG, AND COSMETIC ACT * * * * * * * CHAPTER V--DRUGS AND DEVICES Subchapter A--Drugs and Devices * * * * * * * SEC. 505G. REGULATION OF CERTAIN NONPRESCRIPTION DRUGS THAT ARE MARKETED WITHOUT AN APPROVED DRUG APPLICATION. (a) Nonprescription Drugs Marketed Without an Approved Application.--Nonprescription drugs marketed without an approved drug application under section 505, as of the date of the enactment of this section, shall be treated in accordance with this subsection. (1) Drugs subject to a final monograph; category i drugs subject to a tentative final monograph.--A drug is deemed to be generally recognized as safe and effective under section 201(p)(1), not a new drug under section 201(p), and not subject to section 503(b)(1), if-- (A) the drug is-- (i) in conformity with the requirements for nonprescription use of a final monograph issued under part 330 of title 21, Code of Federal Regulations (except as provided in paragraph (2)), the general requirements for nonprescription drugs, and conditions or requirements under subsections (b), (c), and (k); and (ii) except as permitted by an order issued under subsection (b) or, in the case of a minor change in the drug, in conformity with an order issued under subsection (c), in a dosage form that, immediately prior to the date of the enactment of this section, has been used to a material extent and for a material time under section 201(p)(2); or (B) the drug is-- (i) classified in category I for safety and effectiveness under a tentative final monograph that is the most recently applicable proposal or determination issued under part 330 of title 21, Code of Federal Regulations; (ii) in conformity with the proposed requirements for nonprescription use of such tentative final monograph, any applicable subsequent determination by the Secretary, the general requirements for nonprescription drugs, and conditions or requirements under subsections (b), (c), and (k); and (iii) except as permitted by an order issued under subsection (b) or, in the case of a minor change in the drug, in conformity with an order issued under subsection (c), in a dosage form that, immediately prior to the date of the enactment of this section, has been used to a material extent and for a material time under section 201(p)(2). (2) Treatment of sunscreen drugs.--With respect to sunscreen drugs subject to this section, the applicable requirements in terms of conformity with a final monograph, for purposes of paragraph (1)(A)(i), shall be the requirements specified in part 352 of title 21, Code of Federal Regulations, as published on May 21, 1999, beginning on page 27687 of volume 64 of the Federal Register, except that the applicable requirements governing effectiveness and labeling shall be those specified in section 201.327 of title 21, Code of Federal Regulations. (3) Category iii drugs subject to a tentative final monograph; category i drugs subject to proposed monograph or advance notice of proposed rulemaking.--A drug that is not described in paragraph (1), (2), or (4) is not required to be the subject of an application approved under section 505, and is not subject to section 503(b)(1), if-- (A) the drug is-- (i) classified in category III for safety or effectiveness in the preamble of a proposed rule establishing a tentative final monograph that is the most recently applicable proposal or determination for such drug issued under part 330 of title 21, Code of Federal Regulations; (ii) in conformity with-- (I) the conditions of use, including indication and dosage strength, if any, described for such category III drug in such preamble or in an applicable subsequent proposed rule; (II) the proposed requirements for drugs classified in such tentative final monograph in category I in the most recently proposed rule establishing requirements related to such tentative final monograph and in any final rule establishing requirements that are applicable to the drug; and (III) the general requirements for nonprescription drugs and conditions or requirements under subsection (b) or (k); and (iii) in a dosage form that, immediately prior to the date of the enactment of this section, had been used to a material extent and for a material time under section 201(p)(2); or (B) the drug is-- (i) classified in category I for safety and effectiveness under a proposed monograph or advance notice of proposed rulemaking that is the most recently applicable proposal or determination for such drug issued under part 330 of title 21, Code of Federal Regulations; (ii) in conformity with the requirements for nonprescription use of such proposed monograph or advance notice of proposed rulemaking, any applicable subsequent determination by the Secretary, the general requirements for nonprescription drugs, and conditions or requirements under subsection (b) or (k); and (iii) in a dosage form that, immediately prior to the date of the enactment of this section, has been used to a material extent and for a material time under section 201(p)(2). (4) Category ii drugs deemed new drugs.--A drug that is classified in category II for safety or effectiveness under a tentative final monograph or that is subject to a determination to be not generally recognized as safe and effective in a proposed rule that is the most recently applicable proposal issued under part 330 of title 21, Code of Federal Regulations, shall be deemed to be a new drug under section 201(p), misbranded under section 502(ee), and subject to the requirement for an approved new drug application under section 505 beginning on the day that is 180 calendar days after the date of the enactment of this section, unless, before such day, the Secretary determines that it is in the interest of public health to extend the period during which the drug may be marketed without such an approved new drug application. (5) Drugs not grase deemed new drugs.--A drug that the Secretary has determined not to be generally recognized as safe and effective under section 201(p)(1) under a final determination issued under part 330 of title 21, Code of Federal Regulations, shall be deemed to be a new drug under section 201(p), misbranded under section 502(ee), and subject to the requirement for an approved new drug application under section 505. (6) Other drugs deemed new drugs.--Except as provided in subsection (m), a drug is deemed to be a new drug under section 201(p) and misbranded under section 502(ee) if the drug-- (A) is not subject to section 503(b)(1); and (B) is not described in paragraph (1), (2), (3), (4), or (5), or subsection (b)(1)(B). (b) Administrative Orders.-- (1) In general.-- (A) Determination.--The Secretary may, on the initiative of the Secretary or at the request of one or more requestors, issue an administrative order determining whether there are conditions under which a specific drug, a class of drugs, or a combination of drugs, is determined to be-- (i) not subject to section 503(b)(1); and (ii) generally recognized as safe and effective under section 201(p)(1). (B) Effect.--A drug or combination of drugs shall be deemed to not require approval under section 505 if such drug or combination of drugs-- (i) is determined by the Secretary to meet the conditions specified in clauses (i) and (ii) of subparagraph (A); (ii) is marketed in conformity with an administrative order under this subsection; (iii) meets the general requirements for nonprescription drugs; and (iv) meets the requirements under subsections (c) and (k). (C) Standard.--The Secretary shall find that a drug is not generally recognized as safe and effective under section 201(p)(1) if-- (i) the evidence shows that the drug is not generally recognized as safe and effective under section 201(p)(1); or (ii) the evidence is inadequate to show that the drug is generally recognized as safe and effective under section 201(p)(1). (2) Administrative orders initiated by the secretary.-- (A) In general.--In issuing an administrative order under paragraph (1) upon the Secretary's initiative, the Secretary shall-- (i) make reasonable efforts to notify informally, not later than 2 business days before the issuance of the proposed order, the sponsors of drugs who have a listing in effect under section 510(j) for the drugs or
Source: https://api.congress.gov/v3/committee-report/119/hrpt/300